Our Technologies

Immunobiology

• Expertise in isolation and modification of the protein, peptide and carbohydrate antigens using proprietary technological processes.
• Expertise in preparation and handling of high quality antigen-specific affinity purified polyclonal antibodies, ensuring in this way high specificity and sensitivity of diagnostic system.
• Expertise in efficient development of high quality commercial immunoassays using proprietary reagents.
• We translate this expertise into our immunobiological products and use it in our contract R&D projects.

Molecular Biology - CELO Expression System

Chemogen acquired the rights to a novel technology (CELO) for the production of recombinant proteins based on the use of chicken embryonated eggs as a host organism. The CELO system is capable of delivering high quantities of highly purified proteins at low cost. In comparison with current bacterial and yeast host systems, chicken embryos allow the isolation of biologically active proteins free of endotoxins. The combination of high productivity and the ability to express proteins in native form makes the system a unique choice for the biotechnology industry, significantly more favorable than current systems. Beyond its internal benefits, Chemogen believes that CELO technology, once proven commercially feasible, has significant potential future commercial value.

CELO Technology

• CELO expression system is a proprietary and principally new technology for the production of eukaryotic and prokaryotic recombinant proteins based on the use of chicken embryonated eggs as a host organism. The suggested system is capable of delivering high quantities of functionally active eukaryotic proteins at low cost.
• Chicken eggs have been used extensively for the accumulation of compounds such as lysozyme and ovalbumin. They also serve as a source for the production of vaccines for certain viruses, including encephalitis, influenza, rabies, herpes simplex viruses and others. The technologies of infection and cultivation of embryos, as well as protein isolation, are well elaborated and amenable to automation. However, the embryo technology has never been extended to the synthesis of recombinant therapeutic proteins since no recombinant vector for heterologous gene transfection and expression has been reported elsewhere.
• The discovery of Chicken Embryo Lethal Orphan adenovirus (CELO virus) has provided technical ground for the merger between chicken embryo technology and genetic engineering of recombinant proteins. CELO virus has 44 kilobase linear DNA molecule that codes both for early genes necessary for viral replication and host protein synthesis suppression, and for late genes responsible for capsid formation and virion assembly. The products of the late genes are accumulated in much higher amounts and at greater rate than the early gene products. The enormous efficiency of late genes expression is a consequence of outstanding transcription rate from major late promoter (MLP) and selective translation of viral mRNA instead of host mRNAs. This feature of CELO systems allows high levels of expression of the target recombinant proteins.

The mechanisms of translation and post-translational modification of proteins in chickens fully resemble those of other higher eukaryotes such as human and mouse, which enable native folding and post-translational modification of the expressed protein. Compared to bacterial and yeast host systems, chicken embryos allow the isolation of biologically active proteins, free of endotoxins.

The combination of high productivity and the possibility of obtaining proteins in native form makes the system a unique choice for biotechnology, much more favorable than other hosts currently being used. In addition to the advantages of embryonic technology outlined above, the use of CELO virus offers some other unique features favorable for biotechnological applications.